It has been found that multiple lncRNAs were involved in the resistance to platinum drugs in esophageal cancer (Table 4), including oncogenic lncRNAs NSUN2 methylated lncRNA (NMR), colon cancer-associated transcript-1 (CCAT1), taurine up-regulated gene 1 (TUG1), TP73-AS1, prostate cancer associated ncRNA transcript 1 (PCAT-1), AFAP1-AS1, FOXD2-AS1, POU3F3, LINC00337, LINC00152, and tumor suppressive lncRNA tumor suppressor candidate 7 (TUSC7). This evidence concerns the gene FOXD2 and esophageal cancer.